
David Hodl
David is the Vice President of Business Development, Cell Therapy for Invetech. David has over 21 years of experience in product commercialization and business development roles. Prior to joining Invetech David led the Cell Processing business unit of SynGen, commercializing equipment and single-use consumables for manufacturing cell-based therapies. He also spent eight years in a business development role with Becton Dickinson’s Corporate Innovation Center, focusing on commercialization of cell-based and next-generation sequencing technologies. David earned an MBA from North Carolina State University and a BA in biology from Linfield College.
-
24-Jan-2019
-
24-Jan-2019
-
24-Jan-2019